ExploreWatchlistsPricing
  1. JP-listed companies
  2. HEALIOS K.K.
  3. Financials
  4. Capital expenditures

HEALIOS K.K. (4593)

Market cap
¥45B
P/E ratio
Helios develops stem cell treatments for hard-to-treat diseases using both somatic stem cells and iPS cells to create regenerative medicines.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCapital expenditures (Million JPY)YoY (%)
Dec 31, 2025-168+1020.00%
Dec 31, 2024-15-40.00%
Dec 31, 2023-25-87.92%
Dec 31, 2022-207-29.35%
Dec 31, 2021-293-5.79%
Dec 31, 2020-311+230.85%
Dec 31, 2019-94+28.77%
Dec 31, 2018-73+1.95%
Dec 31, 2017-72-20.42%
Dec 31, 2016-90+52.42%
Dec 31, 2015-59

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat